{
    "root": "0017a82d-4f35-4d17-ab5c-4744dc0effdd",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ALYMSYS",
    "value": "20220423",
    "ingredients": [
        {
            "name": "BEVACIZUMAB",
            "code": "2S9ZZM9Q9V"
        },
        {
            "name": "TREHALOSE DIHYDRATE",
            "code": "7YIN7J07X4"
        },
        {
            "name": "POLYSORBATE 20",
            "code": "7T1F30V5YH"
        },
        {
            "name": "SODIUM PHOSPHATE, DIBASIC, ANHYDROUS",
            "code": "22ADO53M6F"
        },
        {
            "name": "SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE",
            "code": "593YOG76RN"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "alymsys vascular endothelial growth factor inhibitor indicated treatment : metastatic colorectal cancer , combination intravenous fluorouracil-based chemotherapy first- second-line treatment . ( 1.1 ) metastatic colorectal cancer , combination fluoropyrimidine-irinotecan- fluoropyrimidine-oxaliplatin-based chemotherapy second-line treatment patients progressed first-line bevacizumab product-containing regimen . ( 1.1 ) limitations : alymsys indicated adjuvant treatment colon cancer . ( 1.1 ) unresectable , locally advanced , recurrent metastatic non-squamous non-small cell lung cancer , combination carboplatin paclitaxel first-line treatment . ( 1.2 ) recurrent glioblastoma adults . ( 1.3 ) metastatic renal cell carcinoma combination interferon alfa . ( 1.4 ) persistent , recurrent , metastatic cervical cancer , combination paclitaxel cisplatin , paclitaxel topotecan . ( 1.5 ) epithelial ovarian , fallopian tube , primary peritoneal cancer combination paclitaxel , pegylated liposomal doxorubicin , topotecan platinum-resistant recurrent disease received 2 prior chemotherapy regimens ( 1.6 )",
    "contraindications": "withhold least 28 days prior elective surgery . administer alymsys 28 days following major surgery adequate wound healing . ( 2.1 ) metastatic colorectal cancer ( 2.2 ) 5 mg/kg every 2 weeks bolus-ifl 10 mg/kg every 2 weeks folfox4 5 mg/kg every 2 weeks 7.5 mg/kg every 3 weeks fluoropyrimidine-irinotecan- fluoropyrimidine-oxaliplatin-based chemotherapy progression first-line bevacizumab product-containing regimen first-line non−squamous non−small cell lung cancer ( 2.3 ) 15 mg/kg every 3 weeks carboplatin paclitaxel recurrent glioblastoma ( 2.4 ) 10 mg/kg every 2 weeks metastatic renal cell carcinoma ( 2.5 ) 10 mg/kg every 2 weeks interferon alfa persistent , recurrent , metastatic cervical cancer ( 2.6 ) 15 mg/kg every 3 weeks paclitaxel cisplatin , paclitaxel topotecan platinum-resistant recurrent epithelial ovarian , fallopian tube primary peritoneal cancer ( 2.7 ) 10 mg/kg every 2 weeks paclitaxel , pegylated liposomal doxorubicin , topotecan given every week 15 mg/kg every 3 weeks topotecan given every 3 weeks administer intravenous infusion ( 2.9 )",
    "warningsAndPrecautions": "alymsys ( bevacizumab-maly ) injection clear slightly opalescent , colorless pale brown , sterile solution intravenous infusion supplied carton containing single-dose vial following strengths packaging configurations : 100 mg/4 ml ( 25 mg/ml ) : carton one vial ( ndc 70121-1754-1 ) ; carton 10 vials ( ndc 70121-1754-7 ) . 400 mg/16 ml ( 25 mg/ml ) : carton one vial ( ndc 70121-1755-1 ) ; carton 10 vials ( ndc 70121-1755-7 ) . store refrigerated 2°c 8°c ( 36°f 46°f ) original carton time protect light . freeze shake vial carton .",
    "adverseReactions": "none .",
    "indications_original": "Alymsys is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. (1.1) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. (1.1) Limitations of Use: Alymsys is not indicated for adjuvant treatment of colon cancer. (1.1) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. (1.2) Recurrent glioblastoma in adults. (1.3) Metastatic renal cell carcinoma in combination with interferon alfa. (1.4) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. (1.5) Epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens (1.6)",
    "contraindications_original": "Withhold for at least 28 days prior to elective surgery. Do not administer Alymsys for 28 days following major surgery and until adequate wound healing. (2.1) Metastatic colorectal cancer (2.2) 5 mg/kg every 2 weeks with bolus-IFL 10 mg/kg every 2 weeks with FOLFOX4 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy after progression on a first-line bevacizumab product-containing regimen First-line non−squamous non−small cell lung cancer (2.3) 15 mg/kg every 3 weeks with carboplatin and paclitaxel Recurrent glioblastoma (2.4) 10 mg/kg every 2 weeks Metastatic renal cell carcinoma (2.5) 10 mg/kg every 2 weeks with interferon alfa Persistent, recurrent, or metastatic cervical cancer (2.6) 15 mg/kg every 3 weeks with paclitaxel and cisplatin, or paclitaxel and topotecan Platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer (2.7) 10 mg/kg every 2 weeks with paclitaxel, pegylated liposomal doxorubicin, or topotecan given every week 15 mg/kg every 3 weeks with topotecan given every 3 weeks Administer as an intravenous infusion (2.9)",
    "warningsAndPrecautions_original": "Alymsys (bevacizumab-maly) injection is a clear to slightly opalescent, colorless to pale brown, sterile solution for intravenous infusion supplied in a carton containing single-dose vial in the following strengths and packaging configurations: \n                  \n                     100 mg/4 mL (25 mg/mL): carton of one vial (NDC 70121-1754-1); carton of 10 vials (NDC 70121-1754-7). \n                     400 mg/16 mL (25 mg/mL): carton of one vial (NDC 70121-1755-1); carton of 10 vials (NDC 70121-1755-7). \n                  \n                  Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton until time of use to protect from light. Do not freeze or shake the vial or carton.",
    "adverseReactions_original": "None."
}